Additionally, a sequential versus combinatorial treatment regimen of anti-PD-1/PD-L1 lead-in before a MAPK inhibitor was shown to maximize antitumor immunity and efficacy in murine models of melanoma, colorectal, and pancreatic cancer [44]. The gene discussed is CD274; the disease is familial pancreatic carcinoma.